Psilocybin and Mental Health

Abstract

Psilocybin, the psychoactive compound found in "magic mushrooms," has emerged as a subject of increasing scientific interest due to its potential therapeutic applications in mental health treatment. Historically used in indigenous rituals for millennia, psilocybin was introduced to Western medicine in the mid-20th century, only to be criminalized during the 1970s in a political context that disproportionately targeted marginalized communities (Hari, 2015; Sessa, 2012). Recent clinical research has reignited global interest, revealing its efficacy in treating depression, anxiety, post-traumatic stress disorder (PTSD), and substance use disorders (Carhart-Harris et al., 2018; Griffiths et al., 2016). Government institutions such as the U.S. Department of Veterans Affairs are now exploring its potential for combat-related trauma (U.S. Department of Veterans Affairs, 2024), and legal frameworks in states like Oregon and Colorado have begun to permit supervised therapeutic use (Oregon Health Authority, 2020). Despite growing support, psilocybin faces significant resistance from the pharmaceutical industry, which stands to lose billions in annual revenue (Nutt et al., 2013). This comprehensive guide explores the historical, spiritual, scientific, and legal dimensions of psilocybin, while presenting contemporary case studies and analyzing industry opposition. Through rigorous examination, this paper offers a nuanced understanding of psilocybin's role in modern mental health care and policy reform.

Introduction

Mental health disorders affect millions worldwide, creating a growing demand for innovative and effective therapeutic interventions. Psilocybin, a naturally occurring psychedelic compound, is gaining recognition as a promising candidate in psychiatric medicine. Traditionally used in religious and healing practices by indigenous cultures, psilocybin has a complex history marked by reverence, controversy, and suppression. The 20th-century criminalization of psilocybin under the U.S. Controlled Substances Act was driven more by political motives than scientific reasoning, disproportionately targeting marginalized communities, including anti-war activists and civil rights advocates (Ehrlichman as cited in Hari, 2015).
In the 21st century, a resurgence of scientific research has repositioned psilocybin as a potential breakthrough therapy for treatment-resistant mental health conditions. Studies from institutions like Johns Hopkins University and Imperial College London have demonstrated its efficacy in treating depression, anxiety, PTSD, and addiction (Carhart-Harris et al., 2018; Griffiths et al., 2016). Additionally, legal reforms in Oregon and Colorado are pioneering structured therapeutic use (Oregon Health Authority, 2020), while federal agencies like the Veterans Administration are funding studies to explore its benefits for combat veterans (U.S. Department of Veterans Affairs, 2024).
Despite promising evidence, the pharmaceutical industry poses a formidable barrier to widespread adoption. As a one-time or infrequently used treatment, psilocybin challenges profit models based on chronic medication use (Nutt et al., 2013). This paper explores psilocybin’s multifaceted role in healing, its socio-political legacy, emerging legal frameworks, and the ethical implications of industry resistance, offering a holistic perspective on its potential to transform mental health care.
It could be time to seek therapy if an issue causes distress or interferes with daily life. Distress can mean negative thoughts, feelings, behaviors, or even a bodily sensation such as pain or fatigue. It is important not to wait until symptoms become severe before going to therapy. It may be best to seek therapy if you are often unhappy or feel overwhelmed and hopeless about issues in your life. Therapy can also help if you cannot focus on work or school, experience addiction, or feel like hurting yourself or someone else.

Psilocybin-containing mushrooms have been used in spiritual and healing practices for thousands of years. Archaeological evidence indicates their use in prehistoric rock art and ceremonial contexts across Mesoamerica. The Aztecs, who referred to these mushrooms as teonanácatl or "flesh of the gods," integrated them into religious ceremonies to commune with deities, access divine insight, and heal physical and emotional ailments (Carod-Artal, 2015).

The arrival of Spanish colonizers in the 16th century marked a violent turning point in the history of indigenous psychedelic use. The Spanish viewed these sacred rituals as heretical, demonic, and a threat to Catholic orthodoxy. The Catholic Church, in conjunction with the Spanish crown, waged a campaign to eradicate indigenous religious practices, including the use of psychedelic mushrooms, which were believed to allow individuals to communicate directly with the divine undermining the Church’s authority as the sole intermediary between God and humanity.

This suppression was institutionalized through the mechanisms of the Spanish Inquisition, which sought to eliminate non-Christian spiritual practices and enforce Catholic doctrine across the New World. Indigenous healers, shamans, and practitioners who used psilocybin mushrooms were often labeled as witches or sorcerers and faced persecution, torture, or execution. Catholic clergy confiscated sacred mushrooms, burned ceremonial artifacts, and substituted Christian sacraments and saints into indigenous cosmologies in an effort to forcibly convert the population and suppress ancestral knowledge (Furst, 1990; Schultes & Hofmann, 1992).

More than just a theological conflict, this was a struggle over epistemological authority. By criminalizing direct mystical experiences—such as those induced by psilocybin—the Church reinforced a hierarchical model of spiritual access. In this model, divine revelation was mediated exclusively through ordained clergy and the institution of the Church, rather than through personal visionary experiences. This theological monopoly directly conflicted with indigenous traditions, where sacred knowledge was experiential and accessible through ritual and communion with the natural world.

Despite centuries of persecution, many indigenous communities preserved their traditions in secrecy, passing down knowledge through oral histories and covert practice. This cultural resilience would later provide the foundation for Western rediscovery of psilocybin in the 20th century and serves as a testament to the enduring power and wisdom of indigenous spirituality.

Discovery by Western Science

Modern awareness of psilocybin began in earnest in 1955 when amateur ethnomycologist R. Gordon Wasson participated in a Mazatec mushroom ceremony led by curandera Maria Sabina in Oaxaca, Mexico. His account, published in Life magazine in 1957, captivated Western audiences and prompted scientific interest (Wasson, 1957). Swiss chemist Albert Hofmann, already famous for discovering LSD, isolated psilocybin and psilocin in 1958, enabling controlled laboratory studies (Hofmann, 1968).
While this discovery introduced psilocybin to the Western world, it had profound and often tragic consequences for Maria Sabina and the Mazatec community. The publicity led to an influx of Westerners seeking psychedelic experiences, many of whom disregarded the sacred context of the rituals. Maria Sabina was ostracized by her community, accused of violating sacred traditions, and blamed for the cultural disruption that followed. Her home was destroyed, her son was murdered, and she ultimately died in poverty in 1985 (Estrada, 1981).
Despite being vilified during her lifetime, Maria Sabina is now celebrated as a visionary healer and cultural icon. Her legacy has been reclaimed in recent years, with recognition of her role in introducing psilocybin to Western science and medicine. Within her community and beyond, she is honored as a woman of deep spiritual wisdom whose courage bridged worlds, albeit at great personal cost (Schultes & Hofmann, 1992; Furst, 1990).

The Psychedelic Revolution and Modern Criminalization

The 1960s saw a surge of interest in psychedelics, including psilocybin, among countercultural figures and researchers. Psychologists like Timothy Leary and Richard Alpert promoted psilocybin for its potential to expand consciousness and foster personal insight (Leary, 1966). However, political backlash and concerns over misuse led to its classification as a Schedule I drug under the U.S. Controlled Substances Act of 1970, halting research and marginalizing therapeutic applications (Drug Enforcement Administration, 1970).

Modern Spiritual Revival

The 21st century has witnessed a revival of psilocybin in spiritual contexts. Psychedelic retreats in countries like Jamaica, Costa Rica, and the Netherlands offer guided ceremonies aimed at personal growth and enlightenment. Religious movements such as the Santo Daime and the Native American Church incorporate psilocybin and other entheogens into their rites, asserting legal protections under religious freedom statutes (Labate & Cavnar, 2014).
In recent years, the United States has witnessed a significant resurgence in the exploration of psilocybin's therapeutic and spiritual applications. This revival is marked by a growing body of scientific research highlighting psilocybin's potential benefits for mental health conditions such as depression, anxiety, PTSD, and addiction. Concurrently, public perception has shifted, leading to legislative changes that reflect a more open attitude toward psychedelic-assisted therapies.

Oregon: Pioneering Legal Psilocybin Services

Oregon made history in November 2020 when voters approved Measure 109, the Oregon Psilocybin Services Act. This groundbreaking legislation established the first legal framework in the U.S. for the regulated use of psilocybin in therapeutic settings. Under this act, adults aged 21 and over can access psilocybin services through licensed service centers, where consumption is supervised by trained and certified facilitators. The program emphasizes a structured approach, requiring preparation, administration, and integration sessions to ensure client safety and support throughout the experience (Oregon Health Authority, 2023).
The Oregon Health Authority (OHA) oversees the licensing of manufacturers, laboratories, service centers, and facilitators. As of mid-2025, the state has licensed multiple service centers and facilitators, with thousands of clients participating in supervised psilocybin sessions. These services are not only attracting residents but also individuals from other states seeking alternative treatments for mental health challenges (OPB, 2023).

Colorado: Embracing Natural Medicine

Following Oregon's lead, Colorado voters passed Proposition 122 in November 2022, also known as the Natural Medicine Health Act. This legislation decriminalized the personal use, possession, and cultivation of certain natural psychedelics, including psilocybin and psilocyn, for adults aged 21 and over. More notably, it established a regulated framework for psilocybin services, allowing licensed facilitators to provide supervised therapeutic sessions (Colorado Public Radio, 2023).
The Colorado Department of Regulatory Agencies (DORA) and the Department of Revenue are responsible for implementing the program, including the licensing of facilitators and healing centers. The first licenses were issued in early 2025, with service centers beginning operations shortly thereafter. These centers offer structured psilocybin sessions, focusing on safety, preparation, and integration, similar to Oregon's model (Stateline, 2025; Rocky Mountain PBS, 2025).
Colorado's approach also includes provisions for individuals to grow their own psilocybin mushrooms for personal use and allows for the sharing (but not the sale) of these substances. The state has established a Natural Medicine Advisory Board to guide the implementation and expansion of the program, with the potential to include other natural psychedelics in the future (DLA Piper, 2023).

A New Era of Psychedelic Therapy

The initiatives in Oregon and Colorado represent a significant shift in the legal and cultural landscape surrounding psychedelics in the United States. By creating regulated environments for psilocybin use, these states acknowledge the compound's potential benefits while prioritizing safety and ethical considerations. This modern spiritual revival reflects a growing recognition of the value of personal, transformative experiences facilitated by psychedelics, echoing ancient practices while adapting to contemporary societal needs.

Psilocybin for Mental Health: Scientific Research and Evidence

Mechanisms of Action in the Brain

Psilocybin is metabolized into psilocin, which binds to serotonin receptors, especially the 5-HT2A receptor. This interaction alters brain connectivity, particularly decreasing activity in the default mode network (DMN), a region associated with self-referential thought and rumination. Disruption of DMN activity correlates with reduced depressive symptoms and increased cognitive flexibility (Carhart-Harris et al., 2012).
Neuroimaging studies reveal that psilocybin fosters increased neural communication across previously disconnected brain regions, promoting new perspectives and emotional insights. This mechanism is believed to underlie its therapeutic efficacy in disorders characterized by rigid thought patterns.

PTSD and Addiction Therapy

Preliminary research suggests that psilocybin may aid individuals with PTSD by allowing them to revisit traumatic memories without emotional overwhelm. Its capacity to facilitate emotional processing and perspective shifts makes it an ideal adjunct to psychotherapy (Mithoefer et al., 2016).
In addiction treatment, psilocybin has shown promise in promoting abstinence from substances like nicotine and alcohol. Studies report that participants often experience a renewed sense of purpose and improved self-control following psilocybin-assisted therapy (Bogenschutz & Johnson, 2016).

Veterans Administration Focus on Psilocybin for PTSD

The U.S. Department of Veterans Affairs (VA) has recently begun exploring psychedelic-assisted therapy for veterans diagnosed with PTSD and co-occurring conditions such as alcohol use disorder (AUD). In collaboration with academic institutions like Yale and Brown, the VA initiated its first federally funded study on MDMA-assisted psychotherapy—a step that opens the door for similar research on psilocybin.
This move reflects growing acknowledgment of the limitations of traditional treatments for combat-related trauma. The VA's exploration of psychedelic therapies is in response to increasing demand from veterans themselves, many of whom have turned to alternative treatments after exhausting standard psychiatric options.
Although the FDA declined to approve MDMA therapy for PTSD in 2024 due to concerns over trial methodology and data reliability, the momentum for psychedelic research continues. Advocacy organizations such as Heroic Hearts Project are working to connect veterans with clinical trials and to promote policy change. The VA’s involvement represents a significant shift toward evaluating the safety and efficacy of psychedelic therapies within mainstream veteran healthcare.

Psilocybin-Assisted Therapy

Psilocybin-assisted therapy typically involves three phases: preparation, the psychedelic session, and integration. In the preparatory phase, patients build rapport with therapists and set intentions. During the session, psilocybin is administered in a controlled, supportive environment. The integration phase helps patients process their experiences and apply insights to daily life (Johnson et al., 2014).
Therapists trained in trauma-informed care and psychedelic facilitation play a crucial role in guiding clients safely through potentially intense experiences. Music, eye masks, and comfortable settings enhance introspection and emotional release.

Initial Intake

Before beginning therapy, clients undergo a comprehensive intake process to determine whether they are appropriate candidates for psilocybin treatment. This evaluation includes an assessment of mental health history, current symptoms, medications, and physical health status. Licensed professionals screen for potential contraindications such as a personal or family history of psychotic disorders (e.g., schizophrenia or bipolar I disorder), unmanaged cardiovascular conditions, or current substance misuse. Individuals with certain psychiatric diagnoses or who are taking medications that may interact negatively with psilocybin (such as MAO inhibitors or SSRIs) may be excluded or require special medical supervision (Johnson et al., 2008; Carhart-Harris et al., 2018).

Preparation

Before the psychedelic experience, patients undergo multiple preparatory meetings with their therapists. These sessions involve building trust, discussing the individual’s mental health history, setting intentions for the journey, and explaining the effects of psilocybin. Clients are encouraged to cultivate a mindset of openness and curiosity. Addressing fears and clarifying expectations are vital components of this phase, which aims to foster a sense of psychological safety (Johnson et al., 2008).
An essential aspect of preparation is obtaining informed consent. Informed consent ensures that participants understand the treatment's scope, including its therapeutic goals, potential psychological effects, risks, and limitations. This process goes beyond simply signing a form; it emphasizes mutual understanding, autonomy, and ethical responsibility. Through informed consent, participants are empowered to make deliberate decisions about their involvement, which in turn enhances trust, reduces anxiety, and supports a collaborative therapeutic environment. Properly informed participants are generally more engaged in the therapeutic process and more likely to integrate their experiences effectively, contributing to better overall outcomes (Gukasyan & Davis, 2022).

Administration

On the day of administration, the session typically takes place in a comfortable, non-clinical setting designed to promote calm and introspection. The patient ingests a measured dose of psilocybin, often in the form of capsules. The experience usually lasts six to eight hours, during which therapists remain present to offer reassurance and support. Patients often wear eye masks and listen to carefully curated music to facilitate internal focus. The session is non-directive; therapists intervene only when needed, allowing the individual’s inner experience to unfold organically (Carhart-Harris et al., 2012).
In states like Oregon and Colorado, where psilocybin services are legally regulated, specific guidelines have been established to ensure safe and responsible administration. In Oregon, the maximum permissible dose in a legal session is 50 milligrams of psilocybin, and the substance must be administered by a licensed facilitator within a state-regulated service center. These centers are required to meet strict safety and operational standards, including privacy requirements, sanitation protocols, and emergency preparedness plans. Facilitators must complete a state-approved training program and be licensed by the Oregon Health Authority (Oregon Health Authority, 2020).
Similarly, in Colorado—where psilocybin was decriminalized and then legalized for therapeutic use through Proposition 122—regulations are being developed under the state’s Natural Medicine Program. Colorado limits personal possession and non-commercial use to adults over the age of 21. While commercial licensing is expected in 2025, current laws permit only non-retail, facilitated use in approved healing centers. Both states prohibit administration in private homes or unsupervised environments, emphasizing controlled, licensed settings to ensure participant safety and integrity of the therapeutic process.
Additional requirements include informed consent, comprehensive intake assessments, and clear guidelines for adverse event responses. These frameworks are designed to standardize care, minimize risk, and support the ongoing legitimacy of psilocybin therapy as it moves toward broader medical acceptance.

Integration

In the days and weeks following the session, integration therapy helps patients process and make meaning of their psychedelic experience. This stage is critical for translating insights into practical changes in thoughts, behaviors, and emotional responses. Integration may involve journaling, therapy discussions, mindfulness practices, and lifestyle adjustments. The goal is to solidify the therapeutic gains and support long-term mental health improvement (Phelps, 2017).
In Oregon and Colorado, the legal frameworks for psilocybin therapy currently require only minimal integration support—typically a single session after the psychedelic experience. However, experienced facilitators and mental health professionals often recommend multiple integration sessions, especially for individuals with complex trauma or deeply rooted psychological patterns. The number of integration sessions needed can vary widely depending on the individual's personal history, therapeutic goals, and the nature of the psychedelic journey.
A comprehensive integration process enhances the long-term efficacy of psilocybin therapy by helping individuals contextualize their experiences, identify actionable insights, and implement meaningful life changes. As the field matures, further emphasis on robust integration practices is likely to become a cornerstone of effective psychedelic-assisted therapy.

Case Studies

Case Study 1: Treatment-Resistant Depression

Jane, a 45-year-old teacher, struggled with depression for over a decade, unresponsive to multiple antidepressants and cognitive-behavioral therapy. After participating in a clinical trial at Johns Hopkins, she received two guided psilocybin sessions. Jane described a profound sense of connection, forgiveness, and self-acceptance. Six months post-treatment, she reported sustained mood improvements and resumed activities she had long abandoned.

Current Legal Landscape

Legal Status by Country (Sample)

United States: Psilocybin remains federally illegal, but local and state-level reforms are progressing. It was officially categorized as a Schedule I drug in 1970 under the Controlled Substances Act—legislation that emerged during President Richard Nixon’s “War on Drugs.” Schedule I substances are designated as having high abuse potential, no accepted medical use, and a lack of safety even under medical supervision.
The decision to classify psilocybin as Schedule I was driven more by political strategy than scientific evaluation. Nixon’s administration aimed to curb the influence of two major groups he viewed as political threats: the anti-war left (especially the counterculture that used psychedelics) and the Black civil rights movement. Former Nixon advisor John Ehrlichman later admitted that associating drugs with these communities allowed the administration to criminalize them selectively and disrupt their activities through targeted arrests and surveillance.
This political manipulation resulted in psilocybin’s marginalization for decades, despite promising early research. Today, reform efforts are gaining traction: cities like Oakland and Washington D.C. have decriminalized personal use, and Colorado and Oregon have legalized psilocybin therapy under regulated conditions (Oregon Health Authority, 2020).
Canada: Health Canada grants Section 56 exemptions for medical use and research. This exemption allows individuals, typically those with terminal illnesses or treatment-resistant mental health conditions, to legally access psilocybin-assisted therapy on compassionate grounds. In recent years, the number of approved exemptions has grown, reflecting increased public interest and recognition of psilocybin's therapeutic value.
Additionally, the Special Access Program (SAP) was amended to allow healthcare practitioners to request psilocybin for patients under specific circumstances where conventional treatments have failed. This program marks a significant policy shift, acknowledging the need for innovative mental health interventions.
Several nonprofit organizations, such as TheraPsil, have played a critical role in advocating for expanded access and educating both the public and policymakers about the potential benefits of psilocybin therapy. TheraPsil has also helped train therapists in administering psilocybin safely and effectively.
While psilocybin remains a Schedule III substance under Canada’s Controlled Drugs and Substances Act—meaning it is illegal to possess, produce, or distribute without government authorization—these developments suggest a slow but steady movement toward broader decriminalization and therapeutic integration.
United Kingdom: Psilocybin is currently classified as a Class A drug under the Misuse of Drugs Act 1971, placing it in the most restrictive legal category alongside heroin and cocaine. This classification deems psilocybin as having no recognized medical use and a high potential for abuse, making it illegal to possess, distribute, or prescribe.
Despite growing evidence of its therapeutic potential, psilocybin remains heavily restricted, and researchers must obtain special Home Office licenses for clinical trials—an often time-consuming and expensive process. However, advocacy groups and some members of Parliament are calling for reclassification to facilitate medical research. The Advisory Council on the Misuse of Drugs has been petitioned to reconsider its scheduling in light of new scientific findings. Public support is also growing, driven by increasing media coverage and patient testimonials.
Netherlands: Psilocybin truffles, which contain the same active compound, are legal and sold in smart shops. (Kuypers et al., 2019).
Brazil, Jamaica, Costa Rica: Psilocybin mushrooms are legal or decriminalized, fostering a growing psychedelic retreat industry (Tupper, 2011).

Resistance from the Pharmaceutical Industry

Economic Threat to Traditional Drug Markets

The widespread adoption of psilocybin-assisted therapy poses a significant threat to the traditional pharmaceutical industry, particularly to companies that produce antidepressants, anxiolytics, and sleep aids. Unlike conventional psychiatric medications that require daily or continuous dosing, psilocybin has demonstrated effectiveness with as few as one or two guided sessions. This disrupts the standard profit model, which relies on long-term medication adherence and recurring prescriptions.
Analysts estimate that the global antidepressant market alone is valued at over $15 billion annually. If even a fraction of patients shift toward psychedelic therapy, pharmaceutical companies could see billions in lost revenue. Similarly, markets for anti-anxiety medications (valued at $10 billion) and addiction treatments could be impacted by the increasing evidence supporting psilocybin's long-lasting therapeutic effects (Nutt et al., 2013).

Lobbying and Regulatory Influence

Pharmaceutical companies have historically played a powerful role in shaping drug policy and funding regulatory research. Industry resistance to psychedelics may include lobbying efforts aimed at maintaining restrictive classifications, influencing public opinion, and funding studies that downplay psychedelic efficacy. According to documents and expert commentary, there is concern that entrenched financial interests may inhibit legislative progress or influence regulatory frameworks to protect their existing markets (Hari, 2015; Sessa, 2012).
These strategies can delay the integration of psilocybin into mainstream healthcare, despite mounting scientific support. While some pharmaceutical firms have begun investing in psychedelic compounds, others perceive their broad-scale adoption as a destabilizing force. The tension highlights a broader clash between profit-driven medicine and emerging therapies that prioritize holistic, time-limited, and often more cost-effective models of care.

Risks, Side Effects, and Ethical Considerations

While psilocybin therapy offers significant promise, it is not without risks. Potential side effects include nausea, increased heart rate, confusion, anxiety, paranoia, and—in rare cases—psychotic episodes, particularly in individuals with a personal or family history of schizophrenia or bipolar disorder (Johnson et al., 2008). Although most adverse effects are transient and self-resolving in a controlled environment, appropriate screening and supervision are essential.
There is also concern about the potential for misuse and psychological dependency. While psilocybin is considered to have low addictive potential compared to other substances, improper or recreational use without therapeutic support can result in negative psychological outcomes, including persistent anxiety or depersonalization (Carbonaro et al., 2016).
Ethical considerations are paramount as psilocybin therapy becomes more widespread. Access to treatment remains limited and often expensive, raising questions about equity. In Oregon, for example, the cost of a single legal psilocybin session can exceed $2,000, placing it out of reach for many who might benefit most. Without systemic efforts to subsidize or integrate these therapies into public health frameworks, there is a risk that psychedelic-assisted therapy will remain a privilege for the wealthy, exacerbating existing health disparities (George et al., 2020).
Additionally, cultural appropriation remains a concern, as traditional knowledge and indigenous practices are increasingly commodified in Western therapeutic models. Respecting the origins of psilocybin use and ensuring that indigenous voices are included in the evolving narrative, is critical to developing a just and respectful global psychedelic movement.

Conclusion

Psilocybin represents a convergence of ancient wisdom, modern neuroscience, and evolving cultural consciousness. From its sacred use in indigenous ceremonies to cutting-edge clinical trials, psilocybin has repeatedly demonstrated its potential to catalyze deep psychological healing and emotional insight. Legal reforms in Oregon and Colorado (Oregon Health Authority, 2020), as well as federal research initiatives such as those undertaken by the Veterans Administration (U.S. Department of Veterans Affairs, 2024), indicate a growing willingness to integrate this compound into mainstream therapeutic practice.
However, formidable challenges remain. The pharmaceutical industry's resistance, rooted in concerns over lost revenue and disruption to traditional drug models, underscores the need for ethical advocacy and equitable policy development (Sessa, 2012; Nutt et al., 2013). Historical injustices—such as the stigmatization of Maria Sabina and the political manipulation of drug laws during the Nixon era—must be acknowledged and addressed to ensure that future implementation is guided by respect, transparency, and community benefit (Furst, 1990; Hari, 2015).
As societal attitudes shift and scientific evidence continues to build, psilocybin stands poised to become a cornerstone of transformative mental health treatment. Its responsible integration requires continued research, robust safety standards, inclusive policy design, and a commitment to making this powerful tool accessible to those in need, regardless of socioeconomic status. With deliberate and ethical stewardship, psilocybin may help usher in a new era of healing and hope for millions suffering from mental health disorders.

References

Bogenschutz, M. P., & Johnson, M. W. (2016). Classic hallucinogens in the treatment of addictions. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 64, 250–258.

Carbonaro, T. M., Bradstreet, M. P., Barrett, F. S., MacLean, K. A., Jesse, R., Johnson, M. W., & Griffiths, R. R. (2016). Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences. Journal of Psychopharmacology, 30(12), 1268–1278.

Carhart-Harris, R. L., et al. (2012). Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proceedings of the National Academy of Sciences, 109(6), 2138–2143.

Carod-Artal, F. J. (2015). Hallucinogenic drugs in pre-Columbian Mesoamerican cultures. Neurología (English Edition), 30(1), 42–49. https://doi.org/10.1016/j.nrleng.2011.07.005

Carhart-Harris, R. L., et al. (2018). Psilocybin with psychological support for treatment-resistant depression: Six-month follow-up. Psychopharmacology, 235(2), 399–408.

Colorado Public Radio. (2023, June 21). Colorado’s new psychedelic law for psilocybin mushrooms explained. https://www.cpr.org/2023/06/21/colorado-psychedelic-law-for-psilocybin-mushrooms/

De Rios, M. D. (1976). Hallucinogens: Cross-Cultural Perspectives.
San Francisco: Chandler & Sharp.

DLA Piper. (2023, January). State psychedelic regulation: Oregon and Colorado taking the lead. https://www.dlapiper.com/en/insights/publications/2023/01/state-psychedelic-regulation-oregon-and-colorado-taking-the-lead/

Drug Enforcement Administration. (1970). Controlled Substances Act.

Ehrlichman, J., as cited in Hari, J. (2015). Chasing the Scream: The First and Last Days of the War on Drugs. Bloomsbury.

Estrada, A. (1981). Maria Sabina: Her Life and Chants. Ross-Erikson.

Furst, P. T. (1990). Flesh of the Gods: The Ritual Use of Hallucinogens. Waveland Press.

George, J. R., Michaels, T. I., Sevelius, J., & Williams, M. T. (2020). The psychedelic renaissance and the limitations of a white-dominant medical framework: A call for indigenous and culturally-informed perspectives. Frontiers in Psychology, 11, 1–5.

Griffiths, R. R., et al. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer. Journal of Psychopharmacology, 30(12), 1181–1197.

Gukasyan, N., & Davis, A. K. (2022). Psilocybin-assisted therapy for depression: How do we advance the field? Expert Review of Neurotherapeutics, 22(4), 317–320.

Hari, J. (2015). Chasing the Scream: The First and Last Days of the War on Drugs. Bloomsbury.

Health Canada. (2021). Special Access Program for psychedelic therapies.

Heroic Hearts Project. (2024). Expanding access to psychedelic therapies for veterans. Retrieved from https://heroicheartsproject.org

Hofmann, A. (1968). LSD: My Problem Child. McGraw-Hill.

Johnson, M. W., Richards, W. A., & Griffiths, R. R. (2014). Human hallucinogen research: Guidelines for safety. Journal of Psychopharmacology, 22(6), 603–610.

Kuypers, K. P. C., Ng, L., Erritzoe, D., Knudsen, G. M., Nichols, D. E., & Ramaekers, J. G. (2019). Microdosing psychedelics: More questions than answers? An overview and suggestions for future research. Journal of Psychopharmacology, 33(9), 1039–1057.

Labate, B. C., & Cavnar, C. (2014). The Therapeutic Use of Ayahuasca. Springer.

Leary, T. (1966). The Psychedelic Experience. Citadel Press.

Mithoefer, M. C., et al. (2016). The safety and efficacy of MDMA-assisted psychotherapy for PTSD. Journal of Psychopharmacology, 30(12), 1181–1197.

Nutt, D., King, L. A., & Nichols, D. E. (2013). Effects of Schedule I drug laws on neuroscience research and treatment innovation. Nature Reviews Neuroscience, 14(8), 577–585.

OPB. (2023, November 29). How Oregon’s legal psilocybin therapy is working—and who it’s helping. Oregon Public Broadcasting. https://www.opb.org/article/2023/11/29/psilocybin-mushrooms-oregon-service-centers-price/

Oregon Health Authority. (2020). Psilocybin Services Section.

Oregon Health Authority. (2023). Oregon Psilocybin Services: What to know. https://oregonhealthnews.oregon.gov/psilocybin-101-what-to-know-about-oregons-psilocybin-services/

Phelps, J. (2017). Developing guidelines and competencies for the training of psychedelic therapists. Journal of Humanistic Psychology, 57(5), 450–487.

Restall, M. (2003). Seven Myths of the Spanish Conquest. Oxford University Press.

Rocky Mountain PBS. (2025, January). Inside Colorado’s first psilocybin healing center. https://www.rmpbs.org/blogs/health/psilocybin-healing-center-colorado/

Schultes, R. E., & Hofmann, A. (1992). Plants of the Gods: Their Sacred, Healing, and Hallucinogenic Powers. Healing Arts Press.

Sessa, B. (2012). The Psychedelic Renaissance: Reassessing the Role of Psychedelic Drugs in 21st Century Psychiatry and Society. Muswell Hill Press.

Stateline. (2025, January 6). Colorado can now issue licenses to psychedelic mushroom therapy facilitators. Pew Charitable Trusts. https://stateline.org/2025/01/06/colorado-can-now-issue-licenses-to-psychedelic-mushroom-therapy-facilitators/
Tupper, K. W. (2011). Psychedelic medicine and the cultural politics of mental illness. Current Drug Abuse Reviews, 4(4), 254–262.

U.S. Department of Veterans Affairs. (2024). VA funds first study on psychedelic-assisted therapy for veterans. Retrieved from https://news.va.gov/press-room/va-funds-first-study-on-psychedelic-assisted-therapy-for-veterans/

Verywell Health. (2024). FDA rejected MDMA for PTSD. Retrieved from https://www.verywellhealth.com/fda-rejected-mdma-for-ptsd-8694833

Wasson, R. G. (1957). Seeking the Magic Mushroom. Life Magazine, May 13.

Journey Therapeutics Marriage and Family Therapy

Journey Therapeutics Marriage and Family Therapy